Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12569 entries
Sorted by: Best Match Show Resources per page
Redox regulation by glutathione needs enzymes.

Frontiers in pharmacology

Berndt C, Lillig CH, Flohé L.
PMID: 25100998
Front Pharmacol. 2014 Jul 17;5:168. doi: 10.3389/fphar.2014.00168. eCollection 2014.

No abstract available.

Cite
Berndt C, Lillig CH, Flohé L. Redox regulation by glutathione needs enzymes. Front Pharmacol. 2014;5:168doi: 10.3389/fphar.2014.00168.
Berndt, C., Lillig, C. H., & Flohé, L. (2014). Redox regulation by glutathione needs enzymes. Frontiers in pharmacology, 5168. https://doi.org/10.3389/fphar.2014.00168
Berndt, Carsten, et al. "Redox regulation by glutathione needs enzymes." Frontiers in pharmacology vol. 5 (2014): 168. doi: https://doi.org/10.3389/fphar.2014.00168
Berndt C, Lillig CH, Flohé L. Redox regulation by glutathione needs enzymes. Front Pharmacol. 2014 Jul 17;5:168. doi: 10.3389/fphar.2014.00168. eCollection 2014. PMID: 25100998; PMCID: PMC4101335.
Copy Download .nbib Format: NLM
Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer.

Frontiers in pharmacology

Rak J.
PMID: 23508692
Front Pharmacol. 2013 Mar 06;4:21. doi: 10.3389/fphar.2013.00021. eCollection 2013.

In multicellular organisms both health and disease are defined by patterns of communication between the constituent cells. In addition to networks of soluble mediators, cells are also programed to exchange complex messages pre-assembled as multimolecular cargo of membraneous structures...

Cite
Rak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol. 2013;4:21doi: 10.3389/fphar.2013.00021.
Rak, J. (2013). Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Frontiers in pharmacology, 421. https://doi.org/10.3389/fphar.2013.00021
Rak, Janusz. "Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer." Frontiers in pharmacology vol. 4 (2013): 21. doi: https://doi.org/10.3389/fphar.2013.00021
Rak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol. 2013 Mar 06;4:21. doi: 10.3389/fphar.2013.00021. eCollection 2013. PMID: 23508692; PMCID: PMC3589665.
Copy Download .nbib Format: NLM
What is synergy? The Saariselkä agreement revisited.

Frontiers in pharmacology

Tang J, Wennerberg K, Aittokallio T.
PMID: 26388771
Front Pharmacol. 2015 Sep 01;6:181. doi: 10.3389/fphar.2015.00181. eCollection 2015.

Many biological or chemical agents when combined interact with each other and produce a synergistic response that cannot be predicted based on the single agent responses alone. However, depending on the postulated null hypothesis of non-interaction, one may end...

Cite
Tang J, Wennerberg K, Aittokallio T. What is synergy? The Saariselkä agreement revisited. Front Pharmacol. 2015;6:181doi: 10.3389/fphar.2015.00181.
Tang, J., Wennerberg, K., & Aittokallio, T. (2015). What is synergy? The Saariselkä agreement revisited. Frontiers in pharmacology, 6181. https://doi.org/10.3389/fphar.2015.00181
Tang, Jing, et al. "What is synergy? The Saariselkä agreement revisited." Frontiers in pharmacology vol. 6 (2015): 181. doi: https://doi.org/10.3389/fphar.2015.00181
Tang J, Wennerberg K, Aittokallio T. What is synergy? The Saariselkä agreement revisited. Front Pharmacol. 2015 Sep 01;6:181. doi: 10.3389/fphar.2015.00181. eCollection 2015. PMID: 26388771; PMCID: PMC4555011.
Copy Download .nbib Format: NLM
The role of the lymphatic system in cholesterol transport.

Frontiers in pharmacology

Huang LH, Elvington A, Randolph GJ.
PMID: 26388772
Front Pharmacol. 2015 Sep 02;6:182. doi: 10.3389/fphar.2015.00182. eCollection 2015.

Reverse cholesterol transport (RCT) is the pathway for removal of peripheral tissue cholesterol and involves transport of cholesterol back to liver for excretion, starting from cellular cholesterol efflux facilitated by lipid-free apolipoprotein A1 (ApoA1) or other lipidated high-density lipoprotein...

Cite
Huang LH, Elvington A, Randolph GJ. The role of the lymphatic system in cholesterol transport. Front Pharmacol. 2015;6:182doi: 10.3389/fphar.2015.00182.
Huang, L. H., Elvington, A., & Randolph, G. J. (2015). The role of the lymphatic system in cholesterol transport. Frontiers in pharmacology, 6182. https://doi.org/10.3389/fphar.2015.00182
Huang, Li-Hao, et al. "The role of the lymphatic system in cholesterol transport." Frontiers in pharmacology vol. 6 (2015): 182. doi: https://doi.org/10.3389/fphar.2015.00182
Huang LH, Elvington A, Randolph GJ. The role of the lymphatic system in cholesterol transport. Front Pharmacol. 2015 Sep 02;6:182. doi: 10.3389/fphar.2015.00182. eCollection 2015. PMID: 26388772; PMCID: PMC4557107.
Copy Download .nbib Format: NLM
Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels.

Frontiers in pharmacology

Dickschen KJ, Willmann S, Hempel G, Block M.
PMID: 28382001
Front Pharmacol. 2017 Mar 14;8:67. doi: 10.3389/fphar.2017.00067. eCollection 2017.

No abstract available.

Cite
Dickschen KJ, Willmann S, Hempel G, et al. Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. Front Pharmacol. 2017;8:67doi: 10.3389/fphar.2017.00067.
Dickschen, K. J., Willmann, S., Hempel, G., & Block, M. (2017). Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. Frontiers in pharmacology, 867. https://doi.org/10.3389/fphar.2017.00067
Dickschen, Kristin J R, et al. "Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels." Frontiers in pharmacology vol. 8 (2017): 67. doi: https://doi.org/10.3389/fphar.2017.00067
Dickschen KJ, Willmann S, Hempel G, Block M. Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. Front Pharmacol. 2017 Mar 14;8:67. doi: 10.3389/fphar.2017.00067. eCollection 2017. PMID: 28382001; PMCID: PMC5361661.
Copy Download .nbib Format: NLM
Global Metabolomics Reveals the Metabolic Dysfunction in Ox-LDL Induced Macrophage-Derived Foam Cells.

Frontiers in pharmacology

Xu W, Wei Z, Dong J, Duan F, Chen K, Chen C, Liu J, Yang X, Chen L, Xiao H, Liu A.
PMID: 28912717
Front Pharmacol. 2017 Aug 31;8:586. doi: 10.3389/fphar.2017.00586. eCollection 2017.

Atherosclerosis (AS) is a chronic disorder of large arteries that is a major risk factors of high morbidity and mortality. Oxidative modification LDL is one of the important contributors to atherogenesis. Macrophages take up ox-LDL and convert into foam...

Cite
Xu W, Wei Z, Dong J, et al. Global Metabolomics Reveals the Metabolic Dysfunction in Ox-LDL Induced Macrophage-Derived Foam Cells. Front Pharmacol. 2017;8:586doi: 10.3389/fphar.2017.00586.
Xu, W., Wei, Z., Dong, J., Duan, F., Chen, K., Chen, C., Liu, J., Yang, X., Chen, L., Xiao, H., & Liu, A. (2017). Global Metabolomics Reveals the Metabolic Dysfunction in Ox-LDL Induced Macrophage-Derived Foam Cells. Frontiers in pharmacology, 8586. https://doi.org/10.3389/fphar.2017.00586
Xu, Wenjuan, et al. "Global Metabolomics Reveals the Metabolic Dysfunction in Ox-LDL Induced Macrophage-Derived Foam Cells." Frontiers in pharmacology vol. 8 (2017): 586. doi: https://doi.org/10.3389/fphar.2017.00586
Xu W, Wei Z, Dong J, Duan F, Chen K, Chen C, Liu J, Yang X, Chen L, Xiao H, Liu A. Global Metabolomics Reveals the Metabolic Dysfunction in Ox-LDL Induced Macrophage-Derived Foam Cells. Front Pharmacol. 2017 Aug 31;8:586. doi: 10.3389/fphar.2017.00586. eCollection 2017. PMID: 28912717; PMCID: PMC5583968.
Copy Download .nbib Format: NLM
Technical Improvement and Application of Hydrodynamic Gene Delivery in Study of Liver Diseases.

Frontiers in pharmacology

Huang M, Sun R, Huang Q, Tian Z.
PMID: 28912718
Front Pharmacol. 2017 Aug 30;8:591. doi: 10.3389/fphar.2017.00591. eCollection 2017.

Development of an safe and efficient

Cite
Huang M, Sun R, Huang Q, et al. Technical Improvement and Application of Hydrodynamic Gene Delivery in Study of Liver Diseases. Front Pharmacol. 2017;8:591doi: 10.3389/fphar.2017.00591.
Huang, M., Sun, R., Huang, Q., & Tian, Z. (2017). Technical Improvement and Application of Hydrodynamic Gene Delivery in Study of Liver Diseases. Frontiers in pharmacology, 8591. https://doi.org/10.3389/fphar.2017.00591
Huang, Mei, et al. "Technical Improvement and Application of Hydrodynamic Gene Delivery in Study of Liver Diseases." Frontiers in pharmacology vol. 8 (2017): 591. doi: https://doi.org/10.3389/fphar.2017.00591
Huang M, Sun R, Huang Q, Tian Z. Technical Improvement and Application of Hydrodynamic Gene Delivery in Study of Liver Diseases. Front Pharmacol. 2017 Aug 30;8:591. doi: 10.3389/fphar.2017.00591. eCollection 2017. PMID: 28912718; PMCID: PMC5582077.
Copy Download .nbib Format: NLM
Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto.

Frontiers in pharmacology

Kono T, Shimada M, Yamamoto M, Kaneko A, Oomiya Y, Kubota K, Kase Y, Lee K, Uezono Y.
PMID: 26300774
Front Pharmacol. 2015 Aug 04;6:159. doi: 10.3389/fphar.2015.00159. eCollection 2015.

Herbal medicines have been used in Japan for more than 1500 years and traditional Japanese medicines (Kampo medicines) are now fully integrated into the modern healthcare system. In total, 148 Kampo formulae are officially approved as prescription drugs and...

Cite
Kono T, Shimada M, Yamamoto M, et al. Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto. Front Pharmacol. 2015;6:159doi: 10.3389/fphar.2015.00159.
Kono, T., Shimada, M., Yamamoto, M., Kaneko, A., Oomiya, Y., Kubota, K., Kase, Y., Lee, K., & Uezono, Y. (2015). Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto. Frontiers in pharmacology, 6159. https://doi.org/10.3389/fphar.2015.00159
Kono, Toru, et al. "Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto." Frontiers in pharmacology vol. 6 (2015): 159. doi: https://doi.org/10.3389/fphar.2015.00159
Kono T, Shimada M, Yamamoto M, Kaneko A, Oomiya Y, Kubota K, Kase Y, Lee K, Uezono Y. Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto. Front Pharmacol. 2015 Aug 04;6:159. doi: 10.3389/fphar.2015.00159. eCollection 2015. PMID: 26300774; PMCID: PMC4523940.
Copy Download .nbib Format: NLM
An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling .

Frontiers in pharmacology

Su T, Bai JX, Chen YJ, Wang XN, Fu XQ, Li T, Guo H, Zhu PL, Wang Y, Yu ZL.
PMID: 28503147
Front Pharmacol. 2017 Apr 28;8:227. doi: 10.3389/fphar.2017.00227. eCollection 2017.

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide. Signal transducer and activator of transcription 3 (STAT3) signaling is constantly activated in CRC, and has been proposed as a pathogenic factor and a therapeutic target...

Cite
Su T, Bai JX, Chen YJ, et al. An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling . Front Pharmacol. 2017;8:227doi: 10.3389/fphar.2017.00227.
Su, T., Bai, J. X., Chen, Y. J., Wang, X. N., Fu, X. Q., Li, T., Guo, H., Zhu, P. L., Wang, Y., & Yu, Z. L. (2017). An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling . Frontiers in pharmacology, 8227. https://doi.org/10.3389/fphar.2017.00227
Su, Tao, et al. "An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling ." Frontiers in pharmacology vol. 8 (2017): 227. doi: https://doi.org/10.3389/fphar.2017.00227
Su T, Bai JX, Chen YJ, Wang XN, Fu XQ, Li T, Guo H, Zhu PL, Wang Y, Yu ZL. An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling . Front Pharmacol. 2017 Apr 28;8:227. doi: 10.3389/fphar.2017.00227. eCollection 2017. PMID: 28503147; PMCID: PMC5408070.
Copy Download .nbib Format: NLM
Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions - Focus on Interactions with Cytochromes P450.

Frontiers in pharmacology

Ryu CS, Klein K, Zanger UM.
PMID: 28396637
Front Pharmacol. 2017 Mar 27;8:159. doi: 10.3389/fphar.2017.00159. eCollection 2017.

Membrane-associated progesterone receptors (MAPR) are a group of four rather small, partially homologous proteins, which share a similar non-covalent heme-binding domain that is related to cytochrome b5, a well-known functional interaction partner of microsomal cytochrome P450 (CYP) monooxygenase systems....

Cite
Ryu CS, Klein K, Zanger UM. Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions - Focus on Interactions with Cytochromes P450. Front Pharmacol. 2017;8:159doi: 10.3389/fphar.2017.00159.
Ryu, C. S., Klein, K., & Zanger, U. M. (2017). Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions - Focus on Interactions with Cytochromes P450. Frontiers in pharmacology, 8159. https://doi.org/10.3389/fphar.2017.00159
Ryu, Chang S, et al. "Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions - Focus on Interactions with Cytochromes P450." Frontiers in pharmacology vol. 8 (2017): 159. doi: https://doi.org/10.3389/fphar.2017.00159
Ryu CS, Klein K, Zanger UM. Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions - Focus on Interactions with Cytochromes P450. Front Pharmacol. 2017 Mar 27;8:159. doi: 10.3389/fphar.2017.00159. eCollection 2017. PMID: 28396637; PMCID: PMC5366339.
Copy Download .nbib Format: NLM
Innovative Strategies to Develop Chemical Categories Using a Combination of Structural and Toxicological Properties.

Frontiers in pharmacology

Batke M, Gütlein M, Partosch F, Gundert-Remy U, Helma C, Kramer S, Maunz A, Seeland M, Bitsch A.
PMID: 27708580
Front Pharmacol. 2016 Sep 21;7:321. doi: 10.3389/fphar.2016.00321. eCollection 2016.

Interest is increasing in the development of non-animal methods for toxicological evaluations. These methods are however, particularly challenging for complex toxicological endpoints such as repeated dose toxicity. European Legislation, e.g., the European Union's Cosmetic Directive and REACH, demands the...

Cite
Batke M, Gütlein M, Partosch F, et al. Innovative Strategies to Develop Chemical Categories Using a Combination of Structural and Toxicological Properties. Front Pharmacol. 2016;7:321doi: 10.3389/fphar.2016.00321.
Batke, M., Gütlein, M., Partosch, F., Gundert-Remy, U., Helma, C., Kramer, S., Maunz, A., Seeland, M., & Bitsch, A. (2016). Innovative Strategies to Develop Chemical Categories Using a Combination of Structural and Toxicological Properties. Frontiers in pharmacology, 7321. https://doi.org/10.3389/fphar.2016.00321
Batke, Monika, et al. "Innovative Strategies to Develop Chemical Categories Using a Combination of Structural and Toxicological Properties." Frontiers in pharmacology vol. 7 (2016): 321. doi: https://doi.org/10.3389/fphar.2016.00321
Batke M, Gütlein M, Partosch F, Gundert-Remy U, Helma C, Kramer S, Maunz A, Seeland M, Bitsch A. Innovative Strategies to Develop Chemical Categories Using a Combination of Structural and Toxicological Properties. Front Pharmacol. 2016 Sep 21;7:321. doi: 10.3389/fphar.2016.00321. eCollection 2016. PMID: 27708580; PMCID: PMC5030828.
Copy Download .nbib Format: NLM
Activation of Endothelial Pro-resolving Anti-Inflammatory Pathways by Circulating Microvesicles from Non-muscular Myosin Light Chain Kinase-Deficient Mice.

Frontiers in pharmacology

Gaceb A, Vergori L, Martinez MC, Andriantsitohaina R.
PMID: 27708581
Front Pharmacol. 2016 Sep 21;7:322. doi: 10.3389/fphar.2016.00322. eCollection 2016.

Microvesicles, small membrane vesicles released from cells, have beneficial and/or deleterious effects in sepsis. We previously reported that non-muscle myosin light chain kinase (nmMLCK) deletion protects mice against endotoxic shock by reducing inflammation. Here, we have evaluated the consequences...

Cite
Gaceb A, Vergori L, Martinez MC, et al. Activation of Endothelial Pro-resolving Anti-Inflammatory Pathways by Circulating Microvesicles from Non-muscular Myosin Light Chain Kinase-Deficient Mice. Front Pharmacol. 2016;7:322doi: 10.3389/fphar.2016.00322.
Gaceb, A., Vergori, L., Martinez, M. C., & Andriantsitohaina, R. (2016). Activation of Endothelial Pro-resolving Anti-Inflammatory Pathways by Circulating Microvesicles from Non-muscular Myosin Light Chain Kinase-Deficient Mice. Frontiers in pharmacology, 7322. https://doi.org/10.3389/fphar.2016.00322
Gaceb, Abderahim, et al. "Activation of Endothelial Pro-resolving Anti-Inflammatory Pathways by Circulating Microvesicles from Non-muscular Myosin Light Chain Kinase-Deficient Mice." Frontiers in pharmacology vol. 7 (2016): 322. doi: https://doi.org/10.3389/fphar.2016.00322
Gaceb A, Vergori L, Martinez MC, Andriantsitohaina R. Activation of Endothelial Pro-resolving Anti-Inflammatory Pathways by Circulating Microvesicles from Non-muscular Myosin Light Chain Kinase-Deficient Mice. Front Pharmacol. 2016 Sep 21;7:322. doi: 10.3389/fphar.2016.00322. eCollection 2016. PMID: 27708581; PMCID: PMC5030219.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12569 entries